Tandem Diabetes Care Inc (Nasdaq:TNDM)
March 21st, 2019
With markets going up Tandem Diabetes Care Inc closed Thursday up 2.62%, a $1.88 increase to close on $73.56. Furthermore it hit a new 52 week high of $74.81. The stock continues to trade well at 1,915.34% of its 52 week low of $3.65.
Forecasts from 12 analysts indicates that Tandem Diabetes Care Inc might decline somewhat (-5.75%), while Finbox has calculated (with very high uncertainty) a fair value price of $56.71.
The market sectors were mixed Thursday with a majority of the sectors trending up. Information Technology saw the biggest increase of the day (2.47%), while Financials saw the biggest drop (-0.30%). Information Technology has seen the biggest year-to-date gain at 18.16%.
Real Estate saw the biggest turnaround from its 5-day performance of -0.72%, as it went up 1.79%. Financials saw a turn around from its 5-day performance of -0.81% trading down -0.30%.
- Information Technology went up with a 2.47% change.
- Real Estate went up with a 1.79% change.
- Consumer Discretionary went up with a 1.32% change.
- Consumer Staples went up with a 1.19% change.
- Utilities went up with a 1.05% change.
- Materials went up with a 1.04% change.
- Industrials went up with a 0.95% change.
- Communication Services went up with a 0.89% change.
- Energy went up with a 0.69% change.
- Healthcare went up with a 0.35% change.
- Financials went down with a -0.30% change.
Tandem Diabetes Care Inc Info
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump’s software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.